Gavox

Quick links to important sections

Gavox

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gavox

What is Gavox? An Overview of Mebendazole

Property Description
Active Ingredient Mebendazole (INN)
Primary Forms Chewable Tablet, Oral Suspension
Pharmacological Class Anthelmintic Agent / Benzimidazole Derivative
General Purpose Combats Intestinal Parasitic Worm Infestations
Origin Synthetic Organic Compound

What Type of Medicine is Gavox (Mebendazole)?

Gavox is a trade name for the medicine containing the active pharmaceutical ingredient Mebendazole, which is classified as an anthelmintic agent, or antiparasitic drug, used to treat infections caused by parasitic worms in the intestines. Mebendazole is a synthetic organic compound derived from the benzimidazole derivative class, recognized globally for its effectiveness against helminthiasis. It is recognized as an essential medicine, a designation that indicates its importance as a core, vital treatment option for public health needs related to these infections. Mebendazole is clinically recognized for its low systemic absorption in the body, meaning the majority of the drug remains concentrated in the digestive tract to target intestinal parasites effectively.


Composition and Available Forms of Mebendazole

The composition of Mebendazole features the parent compound (C16H13N3O3) as the single active constituent, formulated with appropriate pharmaceutical excipients for oral consumption. The drug is typically supplied for administration via the oral route and is commonly offered as a chewable tablet and an oral suspension. The availability of the chewable tablet form is a key distinguishing feature for this drug, as it ensures flexible administration for target audiences that include young children (generally over the age of two) who may have difficulty swallowing conventional solid forms. Mebendazole has an established broad spectrum of activity against several key nematode species, including roundworms and whipworms.


How Does Mebendazole Generally Affect Parasites?

Mebendazole's primary function is to eliminate the parasites through a highly selective physiological action that prevents the worms from surviving. Its mechanism involves two principles: it acts as a microtubule-destabilizing agent by disrupting the essential internal structures of the worm's cells, and it simultaneously blocks the parasite's ability to absorb necessary nutrients, such as glucose. The practical benefit of this targeted, dual-action mechanism is the efficient immobilization and death of susceptible parasitic worms, providing a decisive method for clearing the infection from the host's system.

Regulatory References

  1. NIH MedlinePlus

What side effects are possible with Gavox?

Possible Side Effects and Safety Information

The official safety profile for the medicine containing Cefpodoxime and Clavulanate Acid is categorized by regulatory health authorities based on observed adverse reactions from clinical studies and post-marketing surveillance. This information is organized into frequency categories and System-Organ Classes (SOCs).


Frequency-Classified Adverse Reactions

The following are examples of adverse reactions listed in regulatory documents:

  • Common: Reactions occurring frequently, such as diarrhea, nausea, abdominal pain, and headache are documented as common in the official safety information.
  • Less Common: Reactions reported less frequently include vomiting, dizziness, and various skin rashes.

System-Organ Classes and Serious Reactions

Adverse effects are documented across several systems, including Gastrointestinal disorders (e.g., diarrhea, vomiting), Nervous System disorders (e.g., headache, dizziness), and Blood and Lymphatic System disorders (e.g., transient changes in white blood cell counts).

Serious adverse reactions explicitly listed in regulatory documents include Pseudomembranous Colitis (a severe form of diarrhea) and severe hypersensitivity events, such as Anaphylaxis and severe cutaneous adverse reactions (SCARs) like Stevens-Johnson Syndrome (SJS).


Safety Constraints and Special Populations

This medicine is contraindicated in patients with a known history of severe allergy (hypersensitivity) to Cefpodoxime, any other cephalosporin, or other beta-lactam antibiotics (like penicillins), due to the documented risk of cross-sensitivity.

Specific safety considerations exist for certain groups. For patients with renal impairment, dose adjustments are required to prevent high drug concentrations. Pediatric patients, particularly infants and toddlers, have a documented higher incidence of gastrointestinal effects like diarrhea and diaper rash during treatment, as reported in clinical studies.

Overdose and Emergency Response

Overdose and when to seek help – Official Regulatory Information for Gavox

Feature Official Regulatory Statements
Documented Manifestations: Acute accidental overdose commonly presents with gastrointestinal signs and symptoms, including abdominal cramps, nausea, vomiting, and diarrhea.
Severe/Life-Threatening Outcomes: Serious effects have been reported primarily with substantially higher doses or prolonged duration, including severe blood disorders like agranulocytosis and neutropenia, and organ injury such as hepatitis and glomerulonephritis.
Emergency Actions Required: Immediate medical attention is required for any suspected overdose. Contact a Poison Control Center or emergency services (911) if the patient has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened.
Management & Constraints: No specific antidote is known. Treatment is strictly symptomatic and supportive, and may include the administration of activated charcoal to limit drug absorption.
Population Considerations: Convulsions have been reported in infants below the age of 1 year during post-marketing experience.

The regulatory documents define the overdose profile by listing the expected acute gastrointestinal manifestations and documenting the potential for severe systemic complications, particularly when exposure involves substantially high doses. The labeling explicitly requires contacting emergency services or a poison control center for immediate action in the event of severe clinical signs. Furthermore, the official guidance confirms that no specific antidote exists, directing management toward supportive care and documented procedures like activated charcoal administration.

Therapeutic Uses of Gavox

What Gavox Treats: Main Uses and Benefits

Gavox is a medicine utilized to manage various types of bacterial infections within the body. Its established applications include addressing infections in several systems.


Quick Facts: Therapeutic Domains

  • Bacterial Infections: Used to support the body's response to different types of bacterial-based illnesses.
  • Respiratory Infections: Prescribed for conditions affecting the lungs and airways, such as certain forms of community-acquired pneumonia and bronchitis.
  • Throat and Ear Infections: Indicated for the care of pharyngitis, tonsillitis, and middle ear infections (otitis media) caused by susceptible bacteria.
  • Skin and Soft Tissue Infections: Employed in the treatment of bacterial infections affecting the skin and underlying soft tissues.
  • Urinary Tract Infections (UTIs): Used to address certain bacterial infections of the urinary tract.

Gavox provides support for individuals experiencing bacterial infections by addressing the underlying pathogenic cause, thereby assisting in the resolution of the condition. Specific approved uses and clinical guidance for antibiotic agents containing Cefpodoxime and Clavulanate Acid are defined for these therapeutic classes. It is important to note that this medicine is not appropriate for viral infections, and its use is reserved for instances where a bacterial pathogen is determined to be the cause.

Eligibility and Restrictions for Use

Population Eligibility and Restrictions

Gavox (Mebendazole) eligibility is strictly defined by regulatory criteria regarding age, hypersensitivity, and physiological status.

Populations Approved for Use

The medicine is officially approved for use in adults and children two years of age and older. The same dosage schedule is generally applied to approved adult and pediatric age groups.


Absolute Contraindications

Use of Gavox is contraindicated in several population groups, meaning it must not be used:

  • Individuals with known hypersensitivity to mebendazole or to any component of the formulation.
  • Children below the age of one year. Safety and effectiveness have not been established in this age group.
  • Certain regulatory labels classify use during pregnancy as contraindicated.
  • Patients with rare hereditary metabolic disorders (e.g., fructose intolerance) due to the presence of specific excipients in some formulations.

Conditional Use and Restrictions

  • Children 1 to 2 Years: Use is not recommended unless the prescribing authority determines that the potential benefit strictly justifies the potential risk.
  • Hepatic Function: Patients with impaired liver function should use the medicine with caution, as this condition may affect drug plasma levels.
  • Lactation: Caution should be exercised when administered to nursing mothers.
  • Older Adults: Clinical data on the distinct response of patients 65 years and older is officially classified as insufficient.

What should I know about interactions with other medicines?

The official regulatory profile for Gavox (Mebendazole) is primarily structured around specific drug-drug combinations that modify exposure or carry an official avoidance warning. Co-administration with the medicine Metronidazole is advised to be avoided by regulatory bodies due to documented postmarketing reports of a serious adverse skin reaction known as Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN).

The product's exposure in the body is also subject to pharmacokinetic interactions with specific medicines that alter its metabolism. The co-administration of Cimetidine, which inhibits the metabolic process, is associated with an official increase in Mebendazole's plasma concentrations. Conversely, the co-administration of certain anticonvulsants, including Carbamazepine and Phenytoin, is documented as leading to a reduction in Mebendazole's plasma levels through metabolic induction.

Regulatory documents also define constraints related to the patient's internal condition. For individuals with impaired hepatic function, the official interaction notes indicate that the drug's metabolism and elimination may result in a tendency toward higher systemic exposure of Mebendazole. The medicine is generally permitted to be taken with or without food, as noted in the administration section of the labeling. No mandatory timing separation rules are documented for co-administered substances.

Mechanism of Action

How Gavox Works: Mechanism of Action

Gavox (Mebendazole) employs a dual-action mechanism highly specific to parasitic worms, leading to irreversible structural damage and total energy depletion of the parasite.


Targeting Parasite Structural Integrity

This mechanism centers on Mebendazole's selective inhibition of beta-Tubulin polymerization within the parasite's cells. This binding causes the destabilization of essential microtubules, resulting in the collapse of the cellular cytoskeleton and irreversible degenerative damage, particularly in the worm's digestive tissue.


Blockade of Nutrient Acquisition and Energy Metabolism

Simultaneously, the drug acts as a competitive inhibitor, effectively blocking the parasite's cellular glucose transporters. This action prevents the uptake of energy sources, which causes the worm to deplete its internal glycogen stores and severely reduce ATP synthesis. This combined structural failure and progressive energetic starvation leads to the parasite's immobilization and eventual destruction within the system.

Dosage and Administration Information

How to Use Gavox

Gavox (Cefpodoxime Proxetil) is administered based on standardized protocols. Understanding these administration guidelines is key to its proper use.


Administration Scope

The medicine is designed for oral administration only, typically available as film-coated tablets and an oral suspension. Adult dosing regimens generally range from 100 mg to 400 mg per dose and are usually scheduled twice daily, approximately every 12 hours, for a fixed course of therapy.

Instruction Detail
Route of administration Oral
Dosing schedule (Adults) 100 mg to 400 mg per dose, twice daily (Q 12 h)
Timing in relation to meals Tablets must be taken with food; Oral Suspension may be taken without regard to meals.
Course duration Fixed, short course, typically ranging from 5 to 14 days.

Procedural and Population Constraints

Administration includes specific procedural steps and adjustments. The oral suspension must be reconstituted and shaken well before each use. If a dose is missed, the standard procedure is to take it as soon as remembered, unless it is nearly time for the next dose, in which case the missed dose is skipped.

Regarding specific patient populations, dose interval adjustments are utilized for patients with severe renal impairment (creatinine clearance < 30 mL/min), often resulting in administration every 24 hours. No specific dosage adjustment based on liver function (hepatic impairment) is typically indicated.


These guidelines define the standardized use of Gavox, detailing the necessary frequency, the context of administration (food requirement), and the modifications for specific physiological constraints, such as impaired renal function.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Gavox (Mebendazole)

Evidence Base for Common Intestinal Worm Infections

The core research for Gavox, which contains the active ingredient Mebendazole, focuses on its use against common parasitic infections of the intestine. Studies conducted for this purpose primarily involve Randomized Controlled Trials (RCTs) and Systematic Reviews that combine and evaluate data from multiple trials. These studies primarily examine specific laboratory outcomes, such as measurements of parasite findings, within the observed populations. The discussion will focus on the design of these studies and the specific, laboratory-based outcomes they measured, such as metrics related to the measured reduction of parasite findings.

Research Evidence for Roundworm (Ascariasis)

Research examining the use of Mebendazole for roundworm infection (A. lumbricoides) primarily consists of short-term RCTs. These studies monitored the Parasitological Cure Rate (CR) and the Egg Reduction Rate (ERR), which are laboratory markers used to track the presence of parasite eggs in stool samples. Findings describe patterns observed in the studies that were generally consistent regarding the measured reduction of Ascaris lumbricoides eggs following the administration of the medicine. Long-term outcomes are not fully established, and the evidence contributes to understanding short-term reduction patterns.

Research Evidence for Whipworm (Trichuriasis)

The research landscape for whipworm infection (T. trichiura) includes RCTs and meta-analyses, but studies explored the outcomes of different dosing approaches. Findings indicated that outcomes often varied depending on whether the medicine was administered as a single dose or over multiple days. Research highlights that study findings often appear mixed, and consistency varies across studies, particularly when relying on single-dose regimens for this parasite. The studies explored whether multi-day dosing regimens were associated with different reported cure rate measurements compared to single-dose administration.

Long-Term Data, Follow-up, and Durability of Effect

The research exploring Mebendazole's use for intestinal parasites predominantly features short-term follow-up durations, typically extending only a few weeks post-administration. This means that long-term outcomes are not well characterized, and the sustained pattern of parasite absence and the rates of subsequent reinfection over several months or years are not fully established. Evidence contributes to understanding symptom patterns and short-term changes, but certainty remains low when examining the sustained impact on clinical health markers.

Areas of Research Uncertainty and Study Limitations

Research exploring Mebendazole has several acknowledged limitations. Data for certain groups remain insufficient, and long-term effects are not fully established. Comparative evidence is lacking for certain regimens, and subgroup findings are uncertain. Overall, the available research highlights what is known—and what is still uncertain—about the study findings.

Key Studies & References

  1. A randomized controlled trial comparing mebendazole and albendazole against Ascaris, Trichuris and hookworm infections

Frequently Asked Questions (FAQ)

Common questions about Gavox (FAQ)

Q: What are the most important things to know about Gavox before starting it?

Official documents emphasize that patients should inform a healthcare professional about all known allergies, any history of liver or stomach disease, and all prescription or nonprescription medications, including vitamins and supplements, being taken. This comprehensive review is designed to ensure all relevant safety information is considered.

Q: Is Gavox commonly prescribed outside of the United States?

Yes. The active ingredient in Gavox, Mebendazole, is included on the World Health Organization's (WHO) Essential Medicines List. This designation indicates that regulatory and intergovernmental bodies recognize it as a core treatment option necessary for public health needs related to parasitic infections globally.

Q: Is Gavox used for prevention or only for treatment?

According to the official product information, Gavox is specifically indicated for the treatment of infections caused by certain intestinal worms. The medicine is not officially indicated for general prevention.

Q: How long do most patients stay on Gavox?

The treatment is typically prescribed as a short, fixed course. This can range from a single dose for conditions like pinworm infection to a twice-daily regimen for 3 consecutive days for other common worm infections.

Q: What if Gavox doesn't seem to be working for me after a week?

Official dosing recommendations for several infections advise that if the measured outcome is not achieved three weeks after treatment, a second course of treatment may be advised. The decision for repeat treatment is typically guided by further laboratory assessments.

Q: If I miss a dose of Gavox, what generally happens?

If a dose is missed, official instructions generally advise taking it as soon as it is remembered unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped entirely. Taking a double dose is not advised, and patients should continue the medicine at the next scheduled time.

Q: How quickly does Gavox typically start to work?

Pharmacokinetic data indicates that the active ingredient is absorbed into the bloodstream, with maximum plasma concentrations generally seen 2 to 4 hours after oral administration.

Q: How long does the effect of one dose of Gavox usually last?

Pharmacokinetic studies indicate that the half-life of Mebendazole, which is the time it takes for half of the medicine to be cleared from the system, is typically reported to be between 3 to 9 hours.

Q: What does the research say about the effectiveness of Gavox?

The research base supporting Gavox is structured around its measured ability to achieve two specific laboratory markers: the Parasitological Cure Rate (CR) and the Egg Reduction Rate (ERR) against specific parasitic worms in the populations studied.

Q: What are the most common side effects reported for Gavox?

Official documents list common adverse effects that have been reported, such as gastrointestinal symptoms, including abdominal pain, diarrhea, flatulence, nausea, and vomiting, as well as headache and loss of appetite.

Q: Is it normal to have mild stomach upset when starting Gavox?

Yes, official documents indicate that gastrointestinal symptoms such as abdominal pain, nausea, and vomiting are listed among the common adverse effects reported in association with this medicine.

Q: What is the risk of having an allergic reaction to Gavox?

Official labeling lists hypersensitivity reactions, including severe systemic reactions like anaphylaxis, as having been reported in postmarketing experience. This is why the medicine is contraindicated (must not be used) in people with a known history of severe allergy to Mebendazole.

Q: Does Gavox cause long-term problems or side effects?

Regulatory reports indicate that certain serious adverse effects, including a severe drop in white blood cells (neutropenia and agranulocytosis), have been reported. These effects have been observed particularly in patients receiving dosages substantially higher than recommended or for prolonged treatment courses.

Q: Can Gavox cause mood changes or mental fog?

Nervous System Disorders reported in postmarketing experience include dizziness and convulsions. Official regulatory documents do not explicitly list general mood changes or mental fog as a common or specific adverse reaction.

Q: What does the package insert say about driving or operating machinery while on Gavox?

Official patient information states that this medicine is not likely to affect the ability to drive or use tools or machines. However, patients should be aware that dizziness is a possible adverse effect.

Q: Can older adults use Gavox safely?

Official notes indicate that elderly patients, as well as those with pre-existing conditions like liver or kidney impairment, may require close monitoring during the course of treatment.

Q: Do I need special monitoring (like blood tests) while on Gavox?

Official documents indicate that, for patients receiving higher doses or prolonged treatment, monitoring of blood counts and liver function tests may be considered due to the potential for hematologic (blood-related) effects.

Q: Can I take Gavox if I am lactose intolerant or have specific food allergies?

The composition of some formulations includes non-medicinal ingredients such as saccharin sodium, and the official label notes the presence of excipients that may be relevant to certain hereditary metabolic disorders. Official patient counseling advises patients to check the full list of inactive ingredients against their known allergies.

Q: Can Gavox be taken if I am already taking medication for anxiety or depression?

Official labeling identifies key interactions with other medicines, such as metronidazole and certain anticonvulsants. Patients are advised that a healthcare professional must be informed of all prescription and non-prescription medicines in use.

Q: Is Gavox safe to take with certain heart medications?

Official patient counseling advises informing a healthcare professional about all prescription medications being taken, as specific drug-drug interaction data may not cover all heart medications that may be in use.

Q: Does Gavox interact with alcohol?

Official patient counseling suggests informing a healthcare professional if you use alcohol, as such substances can potentially affect the action of many medications.

Q: Does Gavox interact with grapefruit?

Specific interaction warnings do not include grapefruit; however, official notes caution that the medicine's metabolism and elimination may be affected in patients with impaired hepatic function (liver function).

Q: Is Gavox safe to take if I have high blood pressure?

Official safety documents list low blood pressure (hypotension) as a reported side effect of the medicine. There are no specific warnings or contraindications regarding pre-existing high blood pressure (hypertension).

Q: Are there any known issues combining Gavox with vitamins or supplements?

Official patient counseling advises informing a healthcare professional about all vitamins, nutritional supplements, and herbal remedies being taken, as information on interactions with these non-prescription substances is often not fully established in official drug labels.

Q: What are the pregnancy safety categories associated with Gavox?

Official labeling includes the TGA Pregnancy Category B3 and notes that some authorities classify its use as contraindicated during pregnancy. It also notes that the US FDA has not assigned the old letter-based categories, replacing them with detailed risk statements.

Q: Is Gavox a controlled substance?

The active ingredient, Mebendazole, is not currently listed among the scheduled substances defined by the U.S. Drug Enforcement Administration (DEA).

Q: Is Gavox considered a high-risk medication?

The chemical hazard classification related to its physical properties lists Acute Toxicity - Oral, Category 4; however, the official drug label does not use the specific term "high-risk medication."

Q: Are there any specific activities I should avoid while on Gavox?

The official patient labeling advises taking steps to prevent reinfection, such as frequent hand washing. The labeling also notes that side effects like dizziness may occur, which could affect the ability to perform certain activities.

Q: Do I need to change my diet while using Gavox?

Official instructions state that Gavox can generally be taken with or without food. No specific or general dietary changes beyond this are mandated in the official labeling.

How should Gavox be stored and disposed of?

Storage

Store Gavox at room temperature away from excess heat, light, and moisture, such as in the bathroom. Maintain the drug in its original, securely closed container to protect its integrity and ensure safety. To prevent accidental ingestion or misuse, always keep the medication out of the sight and reach of children and pets. Do not use any Gavox that is expired or shows signs of damage.

Disposal

Unused or expired Gavox should be disposed of promptly and safely. The preferred method for disposal is through an authorized drug take-back program or a DEA-authorized collector, which may be located at certain pharmacies or law enforcement agencies. If a take-back option is not readily available, most medicines can be thrown away in your household trash by first mixing the drug with an undesirable substance, such as used coffee grounds or cat litter, and sealing the mixture in a container to prevent leakage. Do not flush Gavox down a toilet or sink unless specific instructions from the FDA or manufacturer direct you to do so. Scratch out all personal information on the prescription label before disposing of the packaging.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gavox found in:

A-Z Index: